What is Bayer AG's Shariah compliance score?

Bayer AG's (BAYRY) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Bayer AG pass AAOIFI screening?

Bayer AG (BAYRY) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (BAYRY: 102.5%), (3) interest-bearing deposits below 30% (BAYRY: 21.5%), and (4) prohibited income below 5% (BAYRY: 0.6%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Bayer AG stock?

Bayer AG (BAYRY) has a non-permissible income ratio of 0.64%. Muslim investors should purify this percentage of any dividends received and capital gains realized from BAYRY shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Bayer AG for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Bayer AG (BAYRY) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about BAYRY's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Bayer AG (BAYRY) halal? Not Halal. Based on AAOIFI screening, Bayer AG passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

BAYRY: Is Bayer AG Halal?

Not Halal

Bayer AG

OTCHealthcareDE

$10.56

-1.40%

AvoidBorderlineClean

About Bayer AG

Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

Sector: Healthcare · Industry: Drug Manufacturers - General

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 19, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap102.5% / 30.0%

Compliance History

Not Halal, unchanged since Jun 2026.

No status changes recorded since we began tracking.

Tracked since Jun 2026. Updates automatically on each re-screen.

Screened: Jun 19, 2026Fiscal: FY 2025Source: FMP-ADR

Financial Overview

Market Cap

41.5B

Price

$10.56

Sector

Healthcare

Industry

Drug Manufacturers - General

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.53

-0.03%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.01

-0.33%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track BAYRY and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Bayer AG (BAYRY) halal to invest in?

Bayer AG (BAYRY) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Bayer AG get a F compliance rating?

Bayer AG (BAYRY) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 102.5% (limit 30%); interest-bearing deposits of 21.5% (limit 30%); prohibited income of 0.64% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Bayer AG's Shariah verdict?

Bayer AG's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Bayer AG re-screened for Shariah compliance?

Bayer AG (BAYRY) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 19, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.